Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of the patient cohort, and baseline information

From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Age mean (range), years 68.5 (32.5–91.5)
Gender
 Male n (%) 39 (72%)
 Female n (%) 15 (28%)
Primary nodular melanoma
 Yes n (%) 11 (20%)
 No n (%) 41 (76%)
 Undetermined n (%) 2 (4%)
Breslow thickness mean (range), mm 4.11 (0.37–28)
BRAF V600 status
 Wild type n (%) 33 (61%)
 Mutant n (%) 13 (24%)
 Undetermined n (%) 8 (15%)
Previous ipilimumab n (%) 22 (41%)
Previous nivolumab n (%) 0 (0%)
Baseline tumor size before pembrolizumab mean (range), mm 79 (5–247)
Follow-up period median (range), months 9 (2–35)